title: [Regulatory T cells in cancer immunotherapy].
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Nishikawa
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D060908:CTLA-4 Antigen / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D000074324:Ipilimumab; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D054398:Receptors, CCR4; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; C515354:CCR4 protein, human; D060908:CTLA-4 Antigen; D007166:Immunosuppressive Agents; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D054398:Receptors, CCR4; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine